Identification of plasma proteomic markers underlying polygenic risk of type 2 diabetes and related comorbidities
Loesch DP. et al, (2025), Nature Communications, 16
Age and Sex Differences in Efficacy of Treatments for Type 2 Diabetes: A Network Meta-Analysis.
Hanlon P. et al, (2025), JAMA
Osteoprotegerin, Osteopontin, and Osteocalcin Are Associated With Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL.
Maddaloni E. et al, (2025), Diabetes Care, 48, 235 - 242
The Science of Diabetes and a Life of Trials: The 2024 Banting Medal for Scientific Achievement Award Lecture.
Holman RR., (2025), Diabetes, 74, 164 - 174
The legacy effect of hyperglycaemia in type 2 diabetes - Authors' reply.
Adler AI. et al, (2025), Lancet, 405
An analysis on the role of glucagon-like peptide-1 receptor agonists in cognitive and mental health disorders
De Giorgi R. et al, (2025), Nature Mental Health
Cardiovascular Risk Prediction Scores in Type 1 Diabetes: A Systematic Review and Meta-Analysis
Erqou S. et al, (2025), JACC: Advances, 4
Great debate: pre-diabetes is not an evidence-based treatment target for cardiovascular risk reduction.
Marx N. et al, (2024), Eur Heart J, 45, 5117 - 5126
Younger-onset compared with later-onset type 2 diabetes: an analysis of the UK Prospective Diabetes Study (UKPDS) with up to 30 years of follow-up (UKPDS 92).
Lin B. et al, (2024), Lancet Diabetes Endocrinol
Cardiovascular outcomes with exenatide in type 2 diabetes according to ejection fraction: The EXSCEL trial.
Neves JS. et al, (2024), Eur J Heart Fail
The Diabetes Technology Society Error Grid and Trend Accuracy Matrix for Glucose Monitors.
Klonoff DC. et al, (2024), J Diabetes Sci Technol
Inflammatory proteins associated with Alzheimer's disease reduced by a GLP1 receptor agonist: a post hoc analysis of the EXSCEL randomized placebo controlled trial.
Koychev I. et al, (2024), Alzheimers Res Ther, 16
Going beyond randomised controlled trials to assess treatment effect heterogeneity across target populations.
Lugo-Palacios DG. et al, (2024), Health Econ
Evaluation of hydroxychloroquine or chloroquine for the prevention of COVID-19 (COPCOV): A double-blind, randomised, placebo-controlled trial.
Schilling WHK. et al, (2024), PLoS Med, 21
Using QALYs as an outcome for assessing global prediction accuracy in diabetes simulation models
DAKIN H. et al, (2024), Medical decision making
Examining the impact of structural uncertainty across ten type 2 diabetes models: Results from the 2022 Mount Hood Challenge.
Altunkaya J. et al, (2024), Value Health